HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Daratumumab for treatment-refractory acquired idiopathic pure red cell aplasia.

AuthorsNaseema Gangat, Jonathan Bleeker, Douglas Lynch, Horatiu Olteanu, Louis Letendre, Ayalew Tefferi
JournalHaematologica (Haematologica) Vol. 107 Issue 10 Pg. 2523-2526 (10 01 2022) ISSN: 1592-8721 [Electronic] Italy
PMID35678030 (Publication Type: Journal Article)
Chemical References
  • Antibodies, Monoclonal
  • daratumumab
Topics
  • Antibodies, Monoclonal (therapeutic use)
  • Humans
  • Red-Cell Aplasia, Pure (drug therapy)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: